| Non-Small Cell Lung Carcinoma
Retevmo vs Yervoy
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Retevmo vs Yervoy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYervoy has a higher rate of injection site reactions vs Retevmo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yervoy but not Retevmo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Retevmo
Yervoy
At A Glance
Oral
Twice daily
RET kinase inhibitor
IV infusion
Every 3 weeks (monotherapy) or every 6 weeks (combination)
CTLA-4 antagonist
Indications
- Non-Small Cell Lung Carcinoma
- Medullary carcinoma of thyroid
- Thyroid carcinoma
- melanoma
- Renal Cell Carcinoma
- Colorectal Carcinoma
- Liver carcinoma
- Non-Small Cell Lung Carcinoma
- Malignant Pleural Mesothelioma
- Squamous cell carcinoma of esophagus
Dosing
Non-Small Cell Lung Carcinoma, Medullary carcinoma of thyroid, Thyroid carcinoma Adults and adolescents >= 12 years: 120 mg orally twice daily (< 50 kg) or 160 mg orally twice daily (>= 50 kg); pediatric patients 2 to < 12 years: 40 mg three times daily to 160 mg twice daily orally based on body surface area; administered until disease progression or unacceptable toxicity.
Melanoma (unresectable or metastatic) 3 mg/kg IV every 3 weeks for 4 doses, or 3 mg/kg IV with nivolumab 1 mg/kg IV every 3 weeks for 4 doses followed by nivolumab monotherapy
Melanoma (adjuvant) 3 mg/kg IV every 3 weeks for 4 doses, then 3 mg/kg every 12 weeks for up to 4 additional doses
Renal Cell Carcinoma 1 mg/kg IV with nivolumab 3 mg/kg IV every 3 weeks for 4 doses, followed by nivolumab monotherapy
Colorectal Carcinoma 1 mg/kg IV with nivolumab 240 mg or 3 mg/kg IV (weight-based) every 3 weeks for 4 doses, followed by nivolumab monotherapy
Liver carcinoma 3 mg/kg IV with nivolumab 1 mg/kg IV every 3 weeks for up to 4 doses, followed by nivolumab monotherapy
Non-Small Cell Lung Carcinoma 1 mg/kg IV every 6 weeks with nivolumab 360 mg every 3 weeks, or with nivolumab and 2 cycles of platinum-doublet chemotherapy
Malignant Pleural Mesothelioma 1 mg/kg IV every 6 weeks with nivolumab 360 mg every 3 weeks
Squamous cell carcinoma of esophagus 1 mg/kg IV every 6 weeks with nivolumab 3 mg/kg every 2 weeks or 360 mg every 3 weeks
Contraindications
—
—
Adverse Reactions
Most common (>=25%) edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, headache
Serious hepatotoxicity, interstitial lung disease/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, hypersensitivity, tumor lysis syndrome, impaired wound healing, hypothyroidism, slipped capital femoral epiphysis in adolescents
Postmarketing Stevens-Johnson Syndrome
Most common (>=20%) fatigue, diarrhea, rash, pruritus, nausea, pyrexia, musculoskeletal pain, decreased appetite, cough, headache, dyspnea, vomiting, abdominal pain, arthralgia
Serious immune-mediated colitis, hepatitis, pneumonitis, endocrinopathies, nephritis, dermatologic reactions, neurological toxicities, myocarditis, adrenal insufficiency, hypophysitis, hyperthyroidism, hypothyroidism
Pharmacology
Selpercatinib is a kinase inhibitor that selectively inhibits wild-type RET and multiple mutated RET isoforms (including gene fusions and activating point mutations) as well as VEGFR1 and VEGFR3, and at clinically achievable concentrations also inhibits FGFR1, 2, and 3, blocking constitutive RET signaling that acts as an oncogenic driver promoting tumor cell proliferation.
Ipilimumab blocks CTLA-4, a negative regulator of T-cell activity, thereby augmenting T-cell activation and proliferation including tumor-infiltrating T-effector cells and reducing T-regulatory cell function.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Retevmo.
Yervoy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Retevmo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Yervoy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Retevmo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Yervoy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Retevmo.
No savings programs available for Yervoy.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RetevmoView full Retevmo profile
YervoyView full Yervoy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.